Welcome to the Nexus of Ethics, Psychology, Morality, Philosophy and Health Care

Welcome to the nexus of ethics, psychology, morality, technology, health care, and philosophy
Showing posts with label Clinical Dilemma. Show all posts
Showing posts with label Clinical Dilemma. Show all posts

Saturday, February 26, 2022

Experts Are Ringing Alarms About Elon Musk’s Brain Implants

Noah Kirsch
Daily Beast
Posted 25 Jan 2021

Here is an excerpt:

“These are very niche products—if we’re really only talking about developing them for paralyzed individuals—the market is small, the devices are expensive,” said Dr. L. Syd Johnson, an associate professor in the Center for Bioethics and Humanities at SUNY Upstate Medical University.

“If the ultimate goal is to use the acquired brain data for other devices, or use these devices for other things—say, to drive cars, to drive Teslas—then there might be a much, much bigger market,” she said. “But then all those human research subjects—people with genuine needs—are being exploited and used in risky research for someone else’s commercial gain.”

In interviews with The Daily Beast, a number of scientists and academics expressed cautious hope that Neuralink will responsibly deliver a new therapy for patients, though each also outlined significant moral quandaries that Musk and company have yet to fully address.

Say, for instance, a clinical trial participant changes their mind and wants out of the study, or develops undesirable complications. “What I’ve seen in the field is we’re really good at implanting [the devices],” said Dr. Laura Cabrera, who researches neuroethics at Penn State. “But if something goes wrong, we really don't have the technology to explant them” and remove them safely without inflicting damage to the brain.

There are also concerns about “the rigor of the scrutiny” from the board that will oversee Neuralink’s trials, said Dr. Kreitmair, noting that some institutional review boards “have a track record of being maybe a little mired in conflicts of interest.” She hoped that the high-profile nature of Neuralink’s work will ensure that they have “a lot of their T’s crossed.”

The academics detailed additional unanswered questions: What happens if Neuralink goes bankrupt after patients already have devices in their brains? Who gets to control users’ brain activity data? What happens to that data if the company is sold, particularly to a foreign entity? How long will the implantable devices last, and will Neuralink cover upgrades for the study participants whether or not the trials succeed?

Dr. Johnson, of SUNY Upstate, questioned whether the startup’s scientific capabilities justify its hype. “If Neuralink is claiming that they’ll be able to use their device therapeutically to help disabled persons, they’re overpromising because they’re a long way from being able to do that.”

Neuralink did not respond to a request for comment as of publication time.

Monday, December 10, 2018

What makes a ‘good’ clinical ethicist?

Trevor Bibler
Baylor College of Medicine Blog
Originally posted October 12, 2018

Here is an excerpt:

Some hold that the complexity of clinical ethics consultations couldn’t be reduced to multiple-choice questions based on a few sources, arguing that creating multiple-choice questions that reflect the challenges of doing clinical ethics is nearly impossible. Most of the time, the HEC-C Program is careful to emphasize that they are testing knowledge of issues in clinical ethics, not the ethicist’s ability to apply this knowledge to the practice of clinical ethics.

This is a nuanced distinction that may be lost on those outside the field. For example, an administrator might view the HEC-C Program as separating a good ethicist from an inadequate ethicist simply because they have 400 hours of experience and can pass a multiple-choice exam.

Others disagree with the source material (called “core references”) that serves as the basis for exam questions. I believe the core references, if repetitious, are important works in the field. My concern is that these works do not pay sufficient attention to some of the most pressing and challenging issues in clinical ethics today: income inequality, care for non-citizens, drug abuse, race, religion, sex and gender, to name a few areas.

Also, it’s feasible that inadequate ethicists will become certified. I can imagine an ethicist might meet the requirements, but fall short of being a good ethicist because in practice they are poor communicators, lack empathy, are authoritarian when analyzing ethics issues, or have an off-putting presence.

On the other hand, I know some ethicists I would consider experts in the field who are not going to undergo the certification process because they disagree with it. Both of these scenarios show that HEC certification should not be the single requirement that separates a good ethicist from an inadequate ethicist.

The info is here.

Saturday, November 11, 2017

Did I just feed an addiction? Or ease a man’s pain? Welcome to modern medicine’s moral cage fight

Jay Baruch
STAT News
Originally published October 23, 2017

Here are two excerpts:

Will the opioid pills Sonny is asking for treat his pain, feed an addiction, or both? Will prescribing it fulfill my moral responsibility to alleviate his distress, contribute to the supply chain in the illicit pill economy, or both? Prescribing guidelines from the Centers for Disease Control and Prevention and recommendations from medical specialties and local hospitals are well-intentioned and necessary. But they do little to address the central anxiety that makes this decision a source of distress for physicians like me. It’s hard to evaluate pain without making some judgment about the patient and the patient’s story.

(cut)

A good story shortcuts analytical thinking. It can work its charms without our knowledge and sometimes against our better judgment. Once an emotional connection is made and the listener becomes invested in the story, the believability of the story matters less. In fact, the more extreme the story, the greater its capacity to enthrall the listener or reader.

Stories can elicit empathy and influence behavior in part by stimulating the release of the neurotransmitter oxytocin, which has ties to generosity, trustworthiness, and mother-infant bonding. I’m intrigued by the possibility that clinicians’ vulnerability to deceit is often grounded in the empathy they are reported to be lacking.

The article is here.